Effects of New KPD Histocompatibility Policy on Refusal Rate and Transplants R Leishman1, M Aeder2, M S Leffell3, C Murphey4, N Reinsmoen5, S Saidman6,

Slides:



Advertisements
Similar presentations
VIRTUAL PRA AND CROSSMATCHING
Advertisements

Kidney Transplantation Committee Update John J. Friedewald, MD Committee Chair Meetings.
Current CPRA Calculation
PRA = 36% (21/58) Anti-A11 and B44.
Kidney Transplantation Committee Spring Waiting time calculation - pre-registration dialysis time added 2.Candidate classification - Estimated.
Early Outcomes of Transplant Recipients in the OPTN Kidney Paired Donation Pilot Program Mark Aeder, MD, University Hospitals Case Med Center Darren Stewart,
OPTN OPTN Kidney Paired Donation Pilot Program Ruthanne L Hanto RN, MPH Program Manager, OPTN KPDPP Regions 4 Meeting May 11, 2012.
SOLID PHASE IMMUNOASSAYS: INTERPRETING PATTERNS Julie Houp, CHS Johns Hopkins University School of Medicine Division of Immunogenetics and Transplantation.
Kidney Transplantation Committee Spring Waiting time calculation - pre-registration dialysis time added 2.Candidate classification - Estimated.
1 Proposal to Revise OPTN/UNOS Data Release Policies Data Advisory Committee Fall 2015.
Greater Consistency in Candidate and Deceased Donor HLA Typing Requirements Across Organ Types Histocompatibility Committee Spring 2014.
Expanding HLA Typing Requirements (Resolution 10) Histocompatibility Committee Dolly Tyan, PhD Chair.
Ad Hoc Disease Transmission Advisory Committee Fall 2014.
1 Revising Kidney Paired Donation Pilot Program Priority Points Kidney Transplantation Committee Fall 2015.
1 Proposal to Update the HLA Equivalency Tables Histocompatibility Committee Fall 2015.
Ad Hoc Disease Transmission Advisory Committee Fall 2014.
OPTN/UNOS HISTOCOMPATIBILITY COMMITTEE REPORT TO THE BOARD OF DIRECTORS JUNE 25-26, 2012 RICHMOND, VA Nancy L. Reinsmoen, PhD., Chair.
1 Kidney Transplantation Committee Spring Recent Public Comment Proposals  OPTN Kidney Paired Donation (KPD) Priority Points  Changes apply.
The OPTN Kidney Paired Donation Pilot Program (KPDPP): Reaching the Tipping Point in 2013 Ruthanne Leishman, RN,MPH 1, Darren Stewart, MS 1, Catherine.
1 OPTN/UNOS Histocompatibility Committee Fall 2015.
Histocompatibility Committee
The Joint Annual Congress of the American Society of Transplant Surgeons and The American Society of Transplantation Ariella Maghen, BA Research Assistant.
Minority Affairs Committee
Pancreas Transplantation Committee
Improving Allocation of En Bloc Kidneys Public Comment Proposal
Pancreas Transplantation Committee
Living with Kidney Disease & Transplantation
Histocompatibility Committee
Histocompatibility Committee
OPTN Kidney Paired Donation (KPD) Histocompatibility Testing Policies
Kidney allocation to highly sensitized patients
Guidance for ABO Subtyping Organ Donors for Blood Groups A and AB
Marcelo Pando UNOS Region 5 Collaborative March, 2017
OPTN/UNOS Kidney Transplantation Committee
Addressing HLA Typing Errors
Histocompatibility Laboratory Bylaws and Policies Guidance Document
Histocompatibility Committee
Changes to HCC Criteria for Auto Approval
Pancreas Program Functional Inactivity
Region 7 Nominating Guidelines
Minority Affairs Committee Update
Ethical Implications of Multi-Organ Transplants (MOT)
Living Donor Committee
OPTN Kidney Paired Donation (KPD) Histocompatibility Testing Policies
OPTN Histocompatibility Committee
Operations and Safety Committee
Kidney Transplantation Committee
Kidney Transplantation Committee
Living Donor Committee Spring 2014
Guidance on Effective Practices in Broader Distribution
Liver and Intestinal Organ Transplantation Committee
Operations and Safety Committee
Proposal to Notify Patients Having an Extended Inactive Status
OPTN Kidney Paired Donation (KPD) Histocompatibility Testing Policies
OPTN Kidney Paired Donation (KPD) Histocompatibility Testing Policies
Living Donor Committee Spring 2014
Informed Consent for Kidney Paired Donation
Kidney Transplantation Committee
Policy Rewrite Parking Lot Quick Fixes
Kidney Transplantation Committee
Nancy L. Reinsmoen, PhD, Chair
Improving the Efficiency of Organ Placement
Histocompatibility Committee
Histocompatibility Committee
Histocompatibility Committee
OPTN/UNOS Histocompatibility Committee
Histocompatibility Committee
Histocompatibility Committee
Histocompatibility Committee
OPTN/UNOS Histocompatibility Committee
Presentation transcript:

Effects of New KPD Histocompatibility Policy on Refusal Rate and Transplants R Leishman1, M Aeder2, M S Leffell3, C Murphey4, N Reinsmoen5, S Saidman6, T Sandholm7, A Toll1, A Harper1 and NTurgeon8 1UNOS, Richmond, VA; 2Univ Hosp Med Ctr, Cleveland, OH; 3Johns Hopkins Univ, Baltimore, MD; 4SW Immunodiagnostics, San Antonio, TX; 5CedarsSinai Health, Los Angeles, CA; 6Mass Gen Hosp, Boston, MA; 7Carnegie Mellon Univ, Pittsburgh, PA; and 8Emory Univ, Atlanta, GA. ATC 2017 Chicago, IL kidneypaireddonation@unos.org

The Joint Annual Congress of the American Society of Transplant Surgeons and The American Society of Transplantation Ruthanne Leishman RN, MPH OPTN KPDPP Program Manager UNOS, Richmond, VA, USA I have no financial relationships with commercial interests to disclose AND My presentation does not include discussion of off-label or investigational use.

Acknowledgments This analysis reflects work performed on behalf of and in conjunction with the OPTN Kidney Transplantation Committee and the Kidney Paired Donation Work Group. This work was supported wholly or in part by Health Resources and Services Administration contract 234-2005- 370011C. The content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This work was supported by HRSA under the OPTN contract specified here, though the content is solely the responsibility of the authors.

Actual Match Offer Refusals Remaining 48% (n=160) Actual Match Offer Refusals At the 2015 ATC we reported that 1/3 of match offer refusals in the OPTN KPD program were related to a positive crossmatch. Match Runs: Jan-Sep 2014

Background: Crossmatch-related refusal reasons Match Runs: Jan-Sep 2014 (n=52) Virtual +crossmatch can be due to: Non-required donor antigens not entered (HLA-DQA1, HLA-DQB1, and HLA-DPB1) Non-required donor antigens not screened Candidate unacceptable antigens not entered or updated 2/3’s of reported crossmatch related refusals were do to positive virtual crossmatch. Positive virtual crossmatch can occur because there are certain donor antigens that are not required and therefore not entered by the donor hospital, some antigens such as DP and DQ are not screen by the system even if entered, and sometimes the candidate hospital does not enter all the candidate unacceptable. Either because they are willing to look at offers if the unacceptable is weakly positive or they are willing to consider desensitization in combination with KPD.

Solution Implement KPD histocompatibility requirements Goals Reduce the number of match offer refusals related to positive crossmatch Increase match offer success rate (define as # of offers that results in transplantation) To address this problem the KPD WG and Kidney committee developed histocompatibility requirements with the goals of reducing the number of match offer refusals related to positive virtual or actual XM and in doing so hopefully increase the match offer success rate – which is the number of match offers that result in a candidate being transplanted.

KPD Histocompatibility requirements policy Implemented January 21, 2016 Donor HLA-DQA1, HLA-DQB1, and HLA-DPB1 required All donor HLA screened against candidate unacceptable antigens Specific candidate screening requirements Serological split level molecular typing Solid-phase single phenotype or solid-phase single-antigen test to identify unacceptables antigens Candidate unacceptables reviewed by 2 individuals, prior to first match run Retesting candidate: Every 110 days When any potentially sensitizing event occurs When reactivating a candidate, if inactive more than 90 days When a match is refused due to unacceptable physical crossmatch After a public comment period and approval by the UNOS board of directors, the KPD Histocompatibility were programmed into UNEt and implemented January 21, 2016. Among other things, policy includes requirement that all Donor HLA be entered including HLA-DQA1, HLA-DQB1 , and HLA-DPB1; Specific candidate screening requirements include candidate HLA must be performed and reported at the serological split level molecular typing, that solid=phase single phenotype or solid-phase single antigen test is used to idneify unacceptable antigens, that the unaccepatblaes are reviewed by 2 individuals prior to a candidate being in their first match run, and one person must be from the HLA lab, and finally that the candidate must be retested and unacceptables updated every 110 days, when reactivating after 90 days of inactivation, and when a match offer is refused due to an unacceptable physical crossmatch

Methods XM refusal rates were compared for pre (6/2/14–1/21/16) vs post (1/22/16–2/2/2017) policy periods. A logistic regression model analyzed match outcomes of transplanted or not transplanted, controlled for the time periods, candidate CPRA, candidate age, donor age, donor BMI, and donor ABO. XM refusal rates were compared for the pre vs post policy periods using a logistic regression model to analyze match outcomes of transplanted or not transplanted. The model controlled for time period, candidate CPRA, candidate age, donor age, donor BMI and donor ABO

Results – Decrease in XM related refusals Comparing the pre vs post policy period we see a significant decrease in the refusals related to crossmatch from over 28% of match refusals down to under 12%. Of course being a percentage of total match offers the percentage of refusals in the candidate and donor related refusal reasons has increased

Results – Match Success Rate Univariate Analysis Pre-Policy: 5% Post-Policy: 10% p < 0.001 Logistic Model 118% increase in odds Only significant factor after adjusting for other covariates Of the 1543 matches from June 2, 2014 to February 2, 2017, 95 proceeded to transplant. Without controlling for any other variables we see significantly more matches resulted in a transplant after the policy was implemented (10% vs 5%, p < 0.001). Candidate age, candidate CPRA, donor age, BMI and donor blood type were significantly different when comparing the pre- and post-histo policy periods After controlling for candidate CPRA, candidate age, donor age, donor BMI, and donor blood type, matches found in the post policy period compared to the pre-policy period have an increased log odds of proceeding to transplant by 0.78 (p < 0:001). In other words, in the post-policy period we expect to see a 118% increase in the odds of a match proceeding to transplant. Other covariates: CPRA, candidate age, donor age, donor BMI, donor blood type

Discussion Decrease in refusal rate related to unacceptable crossmatches Increase in match success rate Many highly sensitized candidates became ineligible after implementation, decreasing the mean CPRA of matched candidates decreased The mean CPRA of eligible candidates is now increasing as unacceptables are updated. Longer term analysis will determine whether the increased probability of transplant resulted from the policy's intention vs ineligibility of some sensitized candidates. Further improvements to the program will be based on longer term findings. Now looking at donor-related refusal reasons We have seen a decrease in the match refusals related to unacceptable crossmatches. So far the histocompatibility policy has had a positive impact the match success rate. However, the histocompatibility policy required sensitized transplant centers to enter more information on unacceptable antigens. As a result, many sensitized candidates became ineligible for match runs and the candidates that were matched generally had lower CPRA. As required histocompatibility information is entered for sensitized candidates and their donors, and they become re-eligible for match runs we are seeing an increase in the average candidate CPRA eligible for match runs. A longer term analysis is needed to determine if the increase in probability of transplant resulted from the policy’s intention vs ineligibility of some sensitized candidates. Further improvement to the program will be based on longer term findings.

Thank you!